• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    A Glimpse Into The Expert Outlook On Artivion Through 4 Analysts

    7/2/24 12:01:36 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care
    Get the next $AORT alert in real time by email

    In the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives.

    The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 4 0 0 0 0
    Last 30D 1 0 0 0 0
    1M Ago 0 0 0 0 0
    2M Ago 2 0 0 0 0
    3M Ago 1 0 0 0 0

    Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.5, with a high estimate of $30.00 and a low estimate of $25.00. This current average reflects an increase of 10.0% from the previous average price target of $25.00.

    price target chart

    Deciphering Analyst Ratings: An In-Depth Analysis

    The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Frank Takkinen Lake Street Raises Buy $30.00 $28.00
    Rick Wise Stifel Raises Buy $25.00 $22.00
    Mike Matson Needham Raises Buy $30.00 $25.00
    Mike Matson Needham Maintains Buy $25.00 $25.00

    Key Insights:

    • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Artivion. This information provides a snapshot of how analysts perceive the current state of the company.
    • Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Artivion compared to the broader market.
    • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Artivion's stock. This comparison reveals trends in analysts' expectations over time.

    Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Artivion's market standing. Stay informed and make well-considered decisions with our Ratings Table.

    Stay up to date on Artivion analyst ratings.

    If you are interested in following small-cap stock news and performance you can start by tracking it here.

    Discovering Artivion: A Closer Look

    Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.

    Artivion: Delving into Financials

    Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

    Positive Revenue Trend: Examining Artivion's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.06% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

    Net Margin: Artivion's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.71%, the company showcases strong profitability and effective cost management.

    Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.6%, the company showcases effective utilization of equity capital.

    Return on Assets (ROA): Artivion's ROA excels beyond industry benchmarks, reaching 0.95%. This signifies efficient management of assets and strong financial health.

    Debt Management: Artivion's debt-to-equity ratio surpasses industry norms, standing at 1.23. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

    How Are Analyst Ratings Determined?

    Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

    Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

    If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AORT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AORT

    DatePrice TargetRatingAnalyst
    8/13/2025$38.79Buy → Neutral
    Ladenburg Thalmann
    6/17/2025$35.00Buy
    Canaccord Genuity
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Stanton Marshall S. was granted 850 shares, increasing direct ownership by 2% to 45,603 units (SEC Form 5)

    5 - ARTIVION, INC. (0000784199) (Issuer)

    1/28/26 3:53:37 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Davis John E was granted 874 shares, increasing direct ownership by 0.45% to 194,716 units (SEC Form 5)

    5 - ARTIVION, INC. (0000784199) (Issuer)

    1/28/26 3:50:54 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Holloway Jean F was granted 857 shares, increasing direct ownership by 0.55% to 156,950 units (SEC Form 5)

    5 - ARTIVION, INC. (0000784199) (Issuer)

    1/28/26 3:47:08 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting

    1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana.   The NEXUS T

    2/2/26 8:00:00 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results

    ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial results will be released on Thursday, February 12, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8261 a few m

    1/29/26 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports Third Quarter 2025 Financial Results

    Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basisNet income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for ArcevoATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascul

    11/6/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    3/5/25 4:01:01 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artivion downgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann downgraded Artivion from Buy to Neutral and set a new price target of $38.80

    8/13/25 8:00:59 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Artivion with a new price target

    Canaccord Genuity initiated coverage of Artivion with a rating of Buy and set a new price target of $35.00

    6/17/25 7:48:51 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    JMP Securities initiated coverage on Artivion with a new price target

    JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

    10/23/24 6:17:27 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 23, 2023 - FDA Roundup: May 23, 2023

    For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

    5/23/23 4:06:19 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    SEC Filings

    View All

    SEC Form 144 filed by Artivion Inc.

    144 - ARTIVION, INC. (0000784199) (Subject)

    12/17/25 2:50:54 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Artivion Inc.

    10-Q - ARTIVION, INC. (0000784199) (Filer)

    11/7/25 11:41:27 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    11/6/25 4:09:27 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Financials

    Live finance-specific insights

    View All

    Artivion Reports Third Quarter 2025 Financial Results

    Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basisNet income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for ArcevoATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascul

    11/6/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports Second Quarter 2025 Financial Results

    Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basisNet income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025Adjusted EBITDA increased 33% to $24.8 million in the second quarter of 2025 compared to $18.6 million in the second quarter of 2024Exchanged $99.5 million in principal amount of outstanding convertible senior notes due July 1, 2025 for common stock, resulting in the effective retirement of previously issued

    8/7/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports First Quarter 2025 Financial Results

    First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

    5/5/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Leadership Updates

    Live Leadership Updates

    View All

    Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

    Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

    12/6/23 4:15:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Sequana Medical announces results of Special General Meeting of Shareholders

    PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso

    6/26/23 12:00:00 PM ET
    $AORT
    $PHAR
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Elizabeth Hoff Joins Artivion Board of Directors

    ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca

    9/29/22 4:10:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artivion Inc.

    SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

    11/8/24 10:29:29 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Artivion Inc.

    SC 13G - ARTIVION, INC. (0000784199) (Subject)

    3/11/24 5:45:25 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

    SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

    2/14/24 6:18:56 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care